A randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment

ObjectiveThis study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest®) and vaginal progesterone tablets (Endometrin®) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation.Study designOne hundred and thirty-two infertile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest® 400 mg or Endometrin® 100 mg twice daily for 14 days. On days 6 and 16 after ET, they rated side effects and patient convenience into four grades: none, mild, moderate and severe by completing a questionnaire.ResultsNo significant differences in perineal irritation were found on days 6 and 16 after ET between the two groups, although there was a trend of fewer patients with perineal irritation in the Endometrin® group. Significantly more patients in the Endometrin® group had difficulty of administration on day 6 after ET. There were no differences in the hormonal profile on day 6 after ET and IVF outcomes between the two groups.ConclusionThere was no difference in perineal irritation after the use of Cyclogest® suppositories or Endometrin® tablets for luteal phase support although more patients found administration of Endometrin® tablets difficult.